
Cardiovascular Toxicities Take Center Stage at SSCP Annual Conference - Hadi Skouri (@HSkouri) oncodaily.com/voices/hadi-sk…

Hadi N. Skouri M.D.;FESC;FACC ;FHFA; FHFSA;Heart Failure & Heart Transplant :CardioOncology; AUBMC;SSMC-MayoClinic

Cardiovascular Toxicities Take Center Stage at SSCP Annual Conference - Hadi Skouri (@HSkouri) oncodaily.com/voices/hadi-sk…

🫀#HeartFailure26 comes to a close after an incredible few days of science, collaboration, & innovation. In this special message, HFA President Prof. @MarcoMetra reflects on: - The truly global HF community gathered from all over the world - The outstanding quality of science & abstracts presented - Exciting new initiatives including #HFAUnplugged - and The continued growth of the Heart Failure Association community worldwide Thank you to everyone who made #HeartFailure26 such a remarkable congress👏 #HFA_ESC @escardio #HFAmotions

🫀Full house at the #HeartFailure26 Highlights Session! The #HFA_ESC is wrapping up an incredible congress with rapid-fire updates across the entire spectrum of heart failure, from basic science, imaging, to HFrEF, HFpEF, devices, acute HF & nursing. #HeartFailure @escardio @MarcoMetra @WilfriedMullens @GianluSava

Cardiac Glycosides Revisited or they are still here ? DECISION trial DECISION withdrawal and DIGIT-HF For All HFrEF or for a HFrEF phenotype ? Meta analysis results are reassuring ! #HeartFailure26 @AmrAbdin10 @slumberbell @SotiriaLiori @DrSamStraw @jozinetm @corneliacrm

🫀 What happens when long-term low-dose #digoxin is suddenly withdrawn? Blinded withdrawal analysis from the #DECISION trial presented at #HeartFailure26 by Prof. Peter van der Meer: 📍Digoxin withdrawal was associated with a ~7x increase in worsening HF events over just 6 weeks 📍14 worsening HF events occurred after digoxin withdrawal vs only 2 events in placebo withdrawal 📍Withdrawal was accompanied by: ⬆️HR,⬇️ SBP, ⬆️NT-proBNP, ⬇️eGFR 📍⚠️caution when stopping long-term low-dose digoxin in pts with HF & LVEF <=50% @escardio @HFA_President @jozinetm

What I learned the hard way in #HeartFailure care? Not every setback means failure. Sometimes the missed opportunity, rejected papers, difficult case, or moment of being overlooked becomes the experience that sharpens your clinical judgment, resilience, & purpose. In our career, growth often comes quietly: 🫀listening more carefully 🫀staying curious 🫀learning from patients & your mentors 🫀building consistency 🫀showing up again Early-career setbacks can become the foundation for future impact, if we keep going🥹❤️ Fantastic panels & sharing @KlausKWitte @ARakisheva @noshreza @corneliacrm & Floran Sahiti #HFAyoung @escardio @HFA_President @jozinetm @MarcoMetra

🫀Could RAAS inhibition improve hemocompatibility outcomes in patients supported with durable #LVAD therapy? Presented by @ameeshisath at #HeartFailure26: 📍Sustained RAAS inhibitor exposure over 2 years was associated with a 33%⬇️ in hemocompatibility-related adverse events 📍Non-surgical bleeding, particularly GI bleeding, was significantly ⬇️ with RAAS inhibition 📍Outcomes appeared independent of MAP, INR, or aspirin use 📍Combination #RAAS blockade including #MRAs on top of ACE/ARB/ARNI showed greater effectiveness than single-agent RAAS inhibition alone 📍Findings were directionally consistent across both HeartMate 3 & HeartMate II, suggesting a class-level effect rather than device-specific benefit 📍These data support neurohormonal modulation as a complementary strategy alongside LVAD technology to optimize long-term outcomes @escardio @HFA_President #MCS #GDMTworks

💊 Practical algorithm for diuretic resistance in acute HF from #HeartFailure26— this is the slide to save! Start: Furosemide 120-160 mg ↓ Still congested? Add Chlortalidone 12.5-50 mg/24h ↓ Still congested? Tailor to the problem: • Metabolic alkalosis → Acetazolamide 120-500 mg/24h • Hyponatremia → Tolvaptan 15-50 mg/24h • rLVEF + hypopotassemia → MRA 25-100 mg/24h And running through the whole algorithm: ➕ Add iSGLT2 throughout ➕ Add sacubitril/valsartan if LVEF <49% ➕ Consider parenteral route if oral absorption is the issue Clean. Practical. Evidence-based. 💯 (Adapted from de la Espriella R et al. Nefrologia 2021) #CardioTwitter #HeartFailure #Cardiology #Diuretics #HFrEF

🫀Diuretic resistance identifies a particularly high-risk HF phenotype. Insights from a post hoc analysis of TRANSFORM-HF presented by @ambarish4786 at #HeartFailure26: 📍~1 in 5 hospitalized HF patients were classified as high risk for diuretic resistance 📍High diuretic resistance risk was associated with: - 79% higher all-cause mortality - 34% higher hospitalization risk - Less improvement in KCCQ-CSS 📍Torsemide vs Furosemide effects similar across diuretic resistance risk strata 📍Loop diuretic selection alone may not overcome the adverse prognosis associated with diuretic resistance @escardio @HFA_President #DiuresisJedi

🫀#MR in #HF is far more than “mild, moderate, severe”. ⚠️Accurate MR assessment directly influences HF management & outcomes. Excellent overview by @anatimoteo46040 at #HeartFailure26 on how we should assess secondary MR in HF: 📍Mechanism matters: Ventricular vs atrial MR, differentiate early 📍MR grading must be multiparametric, Never rely on a single number alone. 📍Secondary MR is dynamic, Severity may change after: GDMT optimization, CRT, rhythm/rate control, decongestion. ⚠️Reassess before intervention decisions. 📍Multimodality imaging matters, each provide complementary information on anatomy, mechanism, ventricular remodeling, procedural suitability 📍Heart Team discussion is essential. 📍Quantitative parameters matter most when deciding advanced therapies @escardio @EACVIPresident @VictoriaDe32503 #EchoFirst #whyCMR #YesCCT #3DEcho #HeartFailure

🫀DIGIT-HF subgroup analysis presented at #HeartFailure26 by Prof. Udo Bavendiek, explored the efficacy & safety of #digitoxin in #HFrEF according to #AFib status: 📍HFrEF➕AF represented a clinically higher-risk phenotype with more comorbidities & symptoms 📍Digitoxin ⬇️ the composite of all-cause death or first HF hospitalization irrespective of AF status 📍In AF subgroups: ARR 10.5%, NNT 10 for the primary endpoints 📍The apparent benefit seemed more pronounced in patients with AF, mainly driven by reductions in all-cause mortality @escardio @HFA_President @MarcoMetra @JBauersachsMD

Currently ongoing late breaking science session Day2 . Full room! #HFA_ESC #HeartFailure26 @slumberbell @SotiriaLiori @AmrAbdin10 @corneliacrm @jozinetm @HFA_President @SamStraw

A great session on “Controversies in contemporary drug therapy for heart failure” chaired by me and @BiykemB. World renowned speakers. Great interactive discussions. #HeartFailure26 #HFA_ESC @jozinetm @SotiriaLiori @slumberbell @AmrAbdin10 @corneliacrm @DrSamStraw @HFA_President

Don’t miss the moderated e-Poster & Clinical cases corner at #HeartFailure26! ✅ Learn from real-world cases ✅ See the future of HF research 👉 Be part of the conversation #HFA_ESC @jozinetm @AmrAbdin10 @slumberbell @corneliacrm @SotiriaLiori @DrSamStraw @HFA_President

We're live from Barcelona! 🎙️ Follow our #HeartFailure26 SoMe Ambassadors and Social Media Reporters for real-time session coverage and #HFAmotions videos bringing the congress atmosphere straight to you. @jozinetm @corneliacrm @slumberbell @Arakisheva @AmrAbdin10 @SotiriaLiori @HSkouri @DrSamStraw @HFA_President #HFA_ESC

#HeartFailure26 starts TODAY in Barcelona 🇪🇸🫀 🔥One of today’s highlights: Hottest Trials (1): 🗓️ 9 May | ⏰ 13:15–14:15 |📍Room 3 🔹SUBCUT HF II: Subcutaneous furosemide to support earlier discharge in acute HF 🔹REDOX-AHF: Restrictive vs liberal oxygen targets in acute HF 🔹Re-PHIRE: AZD3427 in HF with pulmonary hypertension group 2 🔹PRAISE-MR: ARNI in HFpEF with secondary MR 🔹CONDUCT-AF: Randomized multicentre AF study @escardio @MarcoMetra @jozinetm @WilfriedMullens @GianluSava